The 13-16th of April saw BD at ECCMID 2019. Held in the historic canal city of Amsterdam, we were there to showcase our latest, most innovative diagnostic solutions. Under the banner of ‘The Difference We Make Together – Patient Safety Starts with Innovative Solutions’, our aim was to send to the world a message of the importance of patient safety and how our diagnostic solutions could help provide it. Improving patient safety through innovation, best practices and education cannot happen in isolation. Working together, at every and all levels of responsibility in the hospital, is crucial towards ensuring the prevalence of a culture of patient safety.
Our mission with our full range of diagnostic solutions is to help identify pathogens, guide targeted therapy and prevent adverse patient safety events. Our innovative diagnostic solutions deliver rapid and accurate results to drive optimal patient management.
Four days of excitement, information, technology solutions towards Advancing the World of Health.
ECCMID 2019 provided us with an excellent opportunity to celebrate our latest diagnostic solutions.
Centred around the BD COR™ system and lab automation, our celebration also allowed our customers to share their experiences on how our solutions have impacted their work with laboratories.
Symposium highlights
The BD symposium “Advancing patient management through diagnostic stewardship” featured four renowned experts talk about different approaches towards the management of the challenges posed by antimicrobial resistance.
"I would like to think of diagnostic stewardship as an integrated and holistic approach to the role of specimen management, to the role of clinical diagnostics, microbiology diagnostics, and the provision of timely results and insights to really affect better patient management and care. That is the philosophy of BD through our innovation strategy and our purpose of advancing the world of health."
Key messages
Prof. Dr. med. Hajo Grundmann
Institute for Infection Prevention and Hospital Epidemiology, Freiburg, Germany
Improving the value of routine susceptibility testing in times of rising resistance
Prof. Hajo Grundmann’s presentation analysed the reasons for rising resistance of K. pneumoniae to carbapenem and 3rd generation cephalosporins in Europe. Prof. Grundmann presented the results of the EuSCAPE study which was carried out to address these questions. 455 hospitals from 36 countries participated in the study.
Key messages
Webinar
Prof. Thierry Naas
Bacteriology department, Hôpital de Bicêtre, Paris, France
Screening of carbapenemase producing organisms: a risk based paradigm to advance patient care
Prof.Naas’s presentation examined the phenomenon of carbapenemase resistance in Enterobacteriaceae (CPE) and the factors to be considered for screening using risk-based paradigms. His presentation focused on the need to screen carriers and how such screenings can be done, primarily to avoid the dreaded 2050 scenario.
Key messages
Prof. Antonella Mencacci
Microbiology department, Ospedale S.Maria della Misericordia, Perugia, Italy
Achieving a patient centered approach through lab automation and change management
Prof. Mencacci’s presentation was about the advantages that accrued upon the transition from a manual to an automated laboratory. She spoke about how the change was managed and how automation helped achieve a more patient-centred approach towards diagnosis.
Webinar
Dr. Patrick Murray
Scientific Affairs VP, BD Medical Affairs, United States
The power of information: At the right time and the right place to accelerate decision making
In his presentation, Dr. Murray spoke about diagnostic stewardship as involving the provision of clinically relevant, accurate and timely information to help patient management. He also spoke about how accurate diagnostics delivered on time could help with appropriate use of microbiological diagnostics and avoid inappropriate empirical therapy.
The BD BACTEC™ FX blood culture system builds on the proven history of previous BD BACTEC™ instrumentation, with advanced fluorescence detection technology, exceptional media performance and instrument reliability—adding vial-activated workflow, advanced ergonomics, blood culture observation and customer-focused data management.
BD Synapsys™ solution offers integrated workflow and on-demand insights to empower laboratory staff to impact turnaround time, expedite decision making, improve productivity and simplify compliance.
The BD MAX™ can perform assays to detect a wide range of pathogens. Explore a range of assays for women’s health and STIs, enteric solutions, HAIs and respiratory solutions.